References
- Whitley RJ. Varicella-zoster virus. In: Mandel GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 4th edn, Vol 2, Pt 3, Ch 116; New York: Churchill Livingstone, 1995:1345–51
- Gabutti G, Penna C, Rossi M, et al. The seroepidemiology of varicella in Italy. Epidemiol Infect 2001;126:433–40
- Banz K, Wagenpfeil S, Neiss A, et al. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 2003;21:1256–67
- SPES Sorveglianza pediatri sentinella, Istituto Superiore di Sanità, Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute; http://www.spes.iss.it/. Page last updated October 2006. Accessed December 21, 2006
- Giaquinto C, Sturkenboom M, Mannino S, et al. Epidemiologia ed esiti della varicella in Italia: risultati di uno studio prospettico sui bambini (0–14 anni) seguiti dai pediatri di libera scelta (Studio Pedianet). Ann Ig 2002;14(Suppl 6):21–7
- Coudeville L, Paree F, Lebrun T, et al. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 1999;17:142–51
- Breman JG, Henderson SA. Diagnosis and management of smallpox. N Engl J Med, 2002;346:1300–8
- Choo PW, Donhaue JG, Manson JE. The epidemiology of varicella and its complications. J Infect Dis 1995;172:706–12
- Centers for Disease Control and Prevention. Prevention of varicella updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999;48:1–5 (No. RR06)
- Galil K, Brown C, Lin F, et al. Hospitalizations for varicella in the United States, 1988 to 1999. Pediatr Infect Dis J 2002;21:931–5
- Ziebold C, von Kries R, Lang R, et al. Severe complications of varicella in previously healthy children in Germany: a 1-year survey. Pediatrics 2001;108:E79
- Jackson MA, Burry VF, Olson LC. Complications of varicella requiring hospitalization in previously healthy children. Pediatr Infect Dis J 1992;11:441–5.
- Meyer PA, Seward JF, Jumaan AO, et al. Varicella mortality: trends before vaccine licensure in the United States, 1970–1994. J Infect Dis 2000;182:383–90
- Rawson H, Crampin A, Noah N. Deaths from chickenpox in England and Wales 1995–7: analysis of routine mortality data. BMJ 2001;323: 1091–3
- Vazquez M, LaRussa PS, Gershon AA, et al. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001;344:955–60
- Vessey SJR, Chan CY, Kuter BJ, et al. Childhood vaccination against varicella: persistence of antibody, duration of protection and vaccine efficacy. J Pediatr 2001;139:297–304
- Gialloreti LE, Divizia M, Pica F, et al. Analysis of the cost-effectiveness of varicella vaccine programmes based on an observational survey in the Latium region of Italy. Herpes. 2005;12:33–7
- Coudeville L, Brunot A, Szucs TD, et al. The economic value of childhood varicella vaccination in France and Germany. Value Health 2005;8:209–22
- Demografia in cifre. Istituto Nazionale di Statistica, ISTAT, http://demo.istat.it/. Page updated December 21, 2006. Accessed December 22, 2006
- Davis MM, Patel MS, Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics 2004;114:786–92
- Brunell PA. Varicella in pregnancy, the fetus, and the newborn: problems in management. J Infect Dis 1992;166(Suppl 1):S42–7
- Sewell EC, Jacobson SH, Weniger BG. “Reverse engineering” a formulary selection algorithm to determine the economic value of pentavalent and hexavalent combination vaccines. Pediatr Infect Dis J 2001;20(11 Suppl):S45–56
- Coudeville L, Brunot A, Giaquinto C, et al. Varicella vaccination in Italy: an economic evaluation of different scenarios. Pharmacoeconomics 2004;22:839–55
- Banca d’Italia Eurosistema. Relazione annuale. http://www.bancaditalia.it/pubblicazioni/relann
- Rivaluta.it. Italian inflation rates. http://www.rivaluta.it/inflazione.htm
- Jacobs RJ, Meyerhoff AS. Comparative cost effectiveness of varicella, hepatitis A, and pneumococcal conjugate vaccines. Prev Med 2001;33:639–45
- Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 2003;21:13–38
- Fornaro P, Gandini F, Marin M, et al. Epidemiology and cost analysis of varicella in Italy: results of a sentinel study in the pediatric practice. Pediatr Infect Dis J 1999;18:414–19
- Zotti CM, Maggiorotto G, Migliardi A. I costi della varicella. Ann Ig 2002;14(Suppl 6):29–33
- Thiry N, Beutels B, Tancredi F, et al. An economic evaluation of varicella vaccination in Italian adolescents. Vaccine 2004;22:3546– 62
- Peterson CL, Mascola L, Chao SM, et al. Children hospitalized a prevaccine review for varicella. J Pediatr 1996;129:529–36
- Ciofi Degli Atti M, Salmaso S, Bella A, et al. Pediatric sentinel surveillance of vaccine-preventable diseases in Italy. Pediatr Infect Dis J, 2002;21:763–8
- Ganesan V, Kirkham FJ. Mechanisms of ischaemic stroke after chickenpox. Arch Dis Child 1997;76:522–5
- Deda G, Caksen H, Icagasioglu D, et al. A case of chickenpox associated with facial nerve palsy. Pediatr Dermatol. 2002;19:95–6
- Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005;352:450–8
- Seward JF, Waysom BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States,1995–2000. JAMA 2002;287:606–11
- Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 2004;23:132–7
- Arvin A, Gershon A. Control of varicella: why is a two-dose schedule necessary? Pediatr Infect Dis J. 2006;25:475–6
- Chaves SS, Gargiullo P, Zhang JX, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med 2007;356:1121–9
- Knuf M, Habermehl P, Zepp F, et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J 2006;25:12–18
- Lieberman JM, Williams WR, Miller JM, et al. Consistency Lot Study Group for ProQuad. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J. 2006;25:615–22
- Brisson M, Gay NJ, Edmunds WJ, et al. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002;20:2500–7
- Seward J, Jumaan A, Schmid S. Varicella vaccine revisited. Nat Med 2000;6:1298–300
- Jumaan AO, Yu O, Jackson LA, et al. Herpes zoster incidence before and after declines in varicella incidence associated with varicella vaccination, 1992–2002. J Infect Dis 2005;191:2002–7
- Yih WK, Brook DR, Lett SM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998–2003. BMC Public Health 2005;5:68–78
- Brisson M, Edmunds WJ The cost-effectiveness of varicella vaccination in Canada. Vaccine 2002;20:1113–25